Compare NAII & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAII | XCUR |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 13.7M |
| IPO Year | 1995 | 2017 |
| Metric | NAII | XCUR |
|---|---|---|
| Price | $2.26 | $1.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.4K | ★ 39.3K |
| Earning Date | 05-13-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $132,437,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.60 | N/A |
| 52 Week Low | $2.00 | $1.05 |
| 52 Week High | $4.96 | $9.48 |
| Indicator | NAII | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 53.83 | 46.34 |
| Support Level | $2.10 | $1.18 |
| Resistance Level | $2.49 | $1.49 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 64.26 | 79.09 |
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segments. The company derives the majority of revenue from Private-Label Contract Manufacturing, which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.